



Ronald Witteles

Professor of Medicine (Cardiovascular Medicine)

Medicine - Cardiovascular Medicine

CLINICAL OFFICE (PRIMARY)

- **Heart Failure Program CV Medicine**

300 Pasteur Dr

Falk Bldg CVRC

Stanford, CA 94305

Tel (650) 498-4343 **Fax** (650) 725-1599

Bio

BIO

Dr. Ronald Witteles is a Cardiologist who specializes in the treatment of patients with Heart Failure. He has particular expertise in the treatment of Amyloidosis, Sarcoidosis, and cardiac complications of cancer therapy (sometimes called "CardioOncology"). He serves as Co-Director of the Stanford Amyloid Center, one of the world's leading centers for the care of patients with amyloidosis, and serves as Co-Director of the Stanford Multidisciplinary Sarcoidosis Program. He has been a leader in many worldwide amyloidosis clinical trials. He is Deputy Editor for JACC: CardioOncology, the world's leading journal dedicated to the field of CardioOncology. Dr. Witteles has published extensively in his areas of expertise, and has won many awards for his excellence in both patient care and education. He was recognized by Stanford Cardiovascular Medicine in 2025 with the Clinical Research Excellence Award -- awarded to the faculty member with the most impactful clinical research.

Dr. Witteles serves as Program Director for the Stanford Internal Medicine residency program -- directly supervising the training of more than 140 physicians each year. He was recognized by Stanford in 2020 with the award for 'Program Director of the Year'. He holds board certification in Internal Medicine, Cardiovascular Disease, and Advanced Heart Failure/Transplant Cardiology.

CLINICAL FOCUS

- Amyloidosis
- CardioOncology (cardiac complications of cancer therapy)
- Sarcoidosis
- Heart Failure
- Advanced Heart Failure and Transplant Cardiology

ACADEMIC APPOINTMENTS

- Professor - University Medical Line, Medicine - Cardiovascular Medicine
- Member, Cardiovascular Institute

ADMINISTRATIVE APPOINTMENTS

- Program Director, Internal Medicine Residency Training Program, (2011- present)
- Co-Director, Stanford Amyloid Center, (2008- present)
- Co-Director, Stanford Multidisciplinary Sarcoidosis Program, (2019- present)
- Sr. Associate Program Director, Internal Medicine Residency Training Program, (2009-2011)
- Associate Director, Coronary Care Unit (CCU), (2008-2009)

HONORS AND AWARDS

- Calvin Fentress Research Fellowship, University of Chicago Pritzker School of Medicine (1999)
- M.D. with Honors (highest distinction by U. of Chicago), University of Chicago Pritzker School of Medicine (2000)
- Francis G. Ebaugh, Jr. Research Award, Stanford University Dept. of Internal Medicine (2001, 2002, 2003)
- Outstanding Clinical Teaching Award, Stanford University Dept. of Internal Medicine (2002, 2003)
- Charles Dorsey Armstrong Clinical Excellence Award, Stanford University Dept. of Internal Medicine (2003)
- National Associates' Research Award, American College of Physicians/American Society of Internal Medicine (2004)
- First Author - Selected as one of 10 most important heart failure articles in 2004, Journal of the American College of Cardiology (2005)
- National Research Fellowship Award, Heart Failure Society of America (2006)
- Clinical Excellence Award, Stanford University Division of Cardiovascular Medicine (2006)
- Timothy F. Beckett, Jr. Award for Excellence in Teaching by a Medicine Fellow, Stanford Univ. Dept. of Internal Medicine (2006)
- Clinical Research Award, Stanford Univ. Division of Cardiovascular Medicine (2007)
- First Author - Selected as one of 15 most important heart failure articles in 2007, Journal of the American College of Cardiology (2008)
- David W. Ryland Award for Excellence in Clinical Teaching by a Department of Medicine faculty member, Stanford University Department of Internal Medicine (2009, 2010)

PROFESSIONAL EDUCATION

- Fellowship: Stanford University School of Medicine (2007) CA
- Residency: Stanford University School of Medicine (2004) CA
- Residency: Stanford University School of Medicine (2003) CA
- Internship: Stanford University School of Medicine (2001) CA
- Board Certification: Advanced Heart Failure and Transplant Cardiology, American Board of Internal Medicine (2012)
- Board Certification: Cardiovascular Disease, American Board of Internal Medicine (2007)
- Board Certification: Internal Medicine, American Board of Internal Medicine (2003)
- Chief Resident, Stanford University , Internal Medicine (2004)
- M.D. with Honors, University of Chicago , Medicine (2000)
- B.A., Northwestern University , Biology/Neuroscience (1996)
- F.A.C.P., American College of Physicians , Internal Medicine (2010)
- F.A.C.C., American College of Cardiology , Cardiology (2008)
- Chief Fellow, Stanford University , Cardiovascular Medicine (2007)
- Medical Education: University of Chicago Pritzker (2000) IL

LINKS

- Internal Medicine Residency Training Program: <http://medicine.stanford.edu/education/residency.html>

- Stanford Amyloid Center: <http://med.stanford.edu/amyloidcenter.html>
- Stanford Multidisciplinary Sarcoidosis Program: <http://med.stanford.edu/sarcoidosis.html>
- Get a Second Opinion: <https://stanfordhealthcare.org/second-opinion/overview.html>

Research & Scholarship

CURRENT RESEARCH AND SCHOLARLY INTERESTS

Dr. Witteles' research focuses on three major areas:

1) Amyloidosis -- As Co-Director of the Stanford Amyloid Center, Dr. Witteles works with a team of investigators to explore novel therapies for amyloidosis and to better understand the mechanisms underlying the disease. This work ranges from clinical trials for multiple types of amyloidosis (AL, ATTR), to defining the role of organ transplantation and pacemakers/defibrillators, to partnering with basic science labs to explore basic principles of pathogenesis.

2) CardioOncology (Cardiac toxicity of cancer therapies) -- Studying optimal prevention and treatment strategies for patients who develop heart failure and other cardiac toxicity as a consequence of cancer therapies, as well as studies to better understand the mechanisms/patterns of toxicity for multiple chemotherapeutic agents. Dr. Witteles serves as Deputy Editor for JACC: CardioOncology, the world's leading journal devoted to the field.

3) Sarcoidosis -- As Co-Director of the Stanford Multidisciplinary Sarcoidosis Program, Dr. Witteles studies novel diagnostic modalities to improve the accuracy of disease diagnosis and the ability to follow responses to treatment of the disease, partners with laboratories to understand the pathogenesis of the disease, and studies new treatments for the disease.

CLINICAL TRIALS

- A Phase 3 Study of NTLA-2001 in ATTR-CM, Recruiting
- JANSSEN_Daratumumab, Recruiting
- Alexion 2220, Not Recruiting
- ALN-TTRSC-004, Not Recruiting
- Eidos Open-Label, Not Recruiting
- HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy, Not Recruiting
- IONIS CS2_Eplontersen, Not Recruiting
- Pilot Lenalidomide, Melphalan and Dexamethasone in AL Amyloidosis, Not Recruiting
- Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy, Not Recruiting
- Study of Daratumumab for Decreasing Circulating Antibodies in Sensitized Patients Awaiting Heart Transplantation, Not Specified

Teaching

GRADUATE AND FELLOWSHIP PROGRAM AFFILIATIONS

- Cardiovascular Medicine (Fellowship Program)
- Medicine (Masters Program)

Publications

PUBLICATIONS

- **Avoiding Catastrophe: Understanding Free Light Chain Testing in the Evaluation of ATTR Amyloidosis.** *Circulation. Heart failure*
Witteles, R. M., Liedtke, M.
2021: CIRCHEARTFAILURE120008225
- **Global Longitudinal Strain in Cardio-Oncology.** *Journal of the American College of Cardiology*
Moslehi, J. J., Witteles, R. M.
2021; 77 (4): 402–4
- **Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study.** *European journal of heart failure*
Damy, T., Garcia-Pavia, P., Hanna, M., Judge, D. P., Merlini, G., Gundapaneni, B., Patterson, T. A., Riley, S., Schwartz, J. H., Sultan, M. B., Witteles, R.
2020
- **AL Amyloidosis for the Cardiologist and Oncologist Epidemiology, Diagnosis, and Management** *JACC: CARDIOONCOLOGY*
Witteles, R. M., Liedtke, M.
2019; 1 (1): 117–30
- **Increase in Blood Pressure Associated With Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor** *JACC: CARDIOONCOLOGY*
Waliyany, S., Sainani, K. L., Park, L. S., Zhang, C., Srinivas, S., Witteles, R. M.
2019; 1 (1): 24–36
- **Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice.** *JACC. Heart failure*
Witteles, R. M., Bokhari, S., Damy, T., Elliott, P. M., Falk, R. H., Fine, N. M., Gospodinova, M., Obici, L., Rapezzi, C., Garcia-Pavia, P.
2019
- **Serial Cardiac FDG-PET for the Diagnosis and Therapeutic Guidance of Patients With Cardiac Sarcoidosis** *JOURNAL OF CARDIAC FAILURE*
Ning, N., Guo, H., Iagaru, A., Mitra, E., Fowler, M., Witteles, R.
2019; 25 (4): 307–11
- **A Changing Landscape of Mortality for Systemic Light Chain Amyloidosis.** *JACC. Heart failure*
Barrett, C. D., Dobos, K. n., Liedtke, M. n., Tuzovic, M. n., Haddad, F. n., Kobayashi, Y. n., Lafayette, R. n., Fowler, M. B., Arai, S. n., Schrier, S. n., Witteles, R. M.
2019
- **Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amyloidosis.** *Circulation. Heart failure*
Maurer, M. S., Bokhari, S. n., Damy, T. n., Dorbala, S. n., Drachman, B. M., Fontana, M. n., Grogan, M. n., Kristen, A. V., Lousada, I. n., Nativi-Nicolau, J. n., Cristina Quarta, C. n., Rapezzi, C. n., Ruberg, et al
2019; 12 (9): e006075
- **Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy** *NEW ENGLAND JOURNAL OF MEDICINE*
Maurer, M. S., Schwartz, J. H., Gundapaneni, B., Elliott, P. M., Merlini, G., Waddington-Cruz, M., Kristen, A. V., Grogan, M., Witteles, R., Damy, T., Drachman, B. M., Shah, S. J., Hanna, et al
2018; 379 (11): 1007–16
- **The State of Medical Student Performance Evaluations: Improved Transparency or Continued Obfuscation?** *Academic medicine*
Hom, J., Richman, I., Hall, P., Ahuja, N., Harman, S., Harrington, R., Witteles, R.
2016; 91 (11): 1534-1539
- **Changing outcomes after heart transplantation in patients with amyloid cardiomyopathy** *JOURNAL OF HEART AND LUNG TRANSPLANTATION*
Davis, M. K., Lee, P. H., Witteles, R. M.
2015; 34 (5): 658-666

- **Outcomes after heart transplantation for amyloid cardiomyopathy in the modern era.** *American journal of transplantation*
Davis, M. K., Kale, P., Liedtke, M., Schrier, S., Arai, S., Wheeler, M., Lafayette, R., Coakley, T., Witteles, R. M.
2015; 15 (3): 650-658
- **Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis** *HEART RHYTHM*
Varr, B. C., Zarafshar, S., Coakley, T., Liedtke, M., Lafayette, R. A., Arai, S., Schrier, S. L., Witteles, R. M.
2014; 11 (1): 158-162
- **Variation in Use of Left Ventriculography in the Veterans Affairs Health Care System** *CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES*
Heidenreich, P. A., Lin, S., Knowles, J. W., Perez, M., Maddox, T. M., Ho, M. P., Rumsfeld, J. S., Sahay, A., Massie, B. M., Tsai, T. T., Witteles, R. M.
2013; 6 (6): 687-693
- **Underestimating Cardiac Toxicity in Cancer Trials: Lessons Learned?** *JOURNAL OF CLINICAL ONCOLOGY*
Witteles, R. M., Telli, M.
2012; 30 (16): 1916-1918
- **Use and overuse of left ventriculography** *AMERICAN HEART JOURNAL*
Witteles, R. M., Knowles, J. W., Perez, M., Morris, W. M., Spettell, C. M., Brennan, T. A., Heidenreich, P. A.
2012; 163 (4): 617-?
- **Heart transplantation and cardiac amyloidosis: Approach to screening and novel management strategies** *JOURNAL OF HEART AND LUNG TRANSPLANTATION*
Varr, B. C., Liedtke, M., Arai, S., Lafayette, R. A., Schrier, S. L., Witteles, R. M.
2012; 31 (3): 325-331
- **Chemotherapy-Associated Cardiotoxicity: How Often Does it Really Occur and How Can it Be Prevented?** *HEART FAILURE CLINICS*
Witteles, R. M., Fowler, M. B., Telli, M. L.
2011; 7 (3): 333-?
- **Radiation Therapy for Breast Cancer Buyer Beware** *JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY*
Witteles, R. M.
2011; 57 (4): 453-454
- **Left Ventricular Dysfunction in Patients Receiving Cardiotoxic Cancer Therapies Are Clinicians Responding Optimally?** *JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY*
Yoon, G. J., Telli, M. L., Kao, D. P., Matsuda, K. Y., Carlson, R. W., Witteles, R. M.
2010; 56 (20): 1644-1650
- **Heart Failure in Hispanics** *JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY*
Vivo, R. P., Krim, S. R., Cevik, C., Witteles, R. M.
2009; 53 (14): 1167-1175
- **Clinical problem-solving. Fool's Gold.** *New England journal of medicine*
Leeper, N. J., Dhaliwal, G., Saint, S., Witteles, R. M.
2008; 359 (19): 2035-2041
- **Insulin-resistant cardiomyopathy** *JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY*
Witteles, R. M., Fowler, M. B.
2008; 51 (2): 93-102
- **Impact of nesiritide on renal function in patients with acute decompensated failure an pre-existing renal dysfunction - A randomized, double-blind, placebo-controlled clinical trial** *JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY*
Witteles, R. M., Kao, D., Christopherson, D., Matsuda, K., Vagelos, R. H., Schreiber, D., Fowler, M. B.
2007; 50 (19): 1835-1840
- **Cardiomyopathy of insulin resistance.** *Heart failure clinics*
Witteles, R. M., Fowler, M. B.
2006; 2 (1): 13-23

- **Insulin resistance in idiopathic dilated cardiomyopathy - A possible etiologic link** *JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY*
Witteles, R. M., Tang, W. H., Jamali, A. H., Chu, J. W., Reaven, G. M., Fowler, M. B.
2004; 44 (1): 78-81
- **Osimertinib-Associated Cardiomyopathy In Patients With Non-Small Cell Lung Cancer: A Case Series** *JACC: CardioOncology*
Franquiz, M., Waliyany, S., Xu, A., Hnatiuk, A., Wu, S., Cheng, P., Wakelee, H., Neal, J., Witteles, R., Zhu, H.
2023: 839-841
- **Immunotherapy-Associated Atherosclerosis: A Comprehensive Review of Recent Findings and Implications for Future Research** *Current Treatment Options in Cardiovascular Medicine*
Chan, A., Torelli, S., Cheng, E., Batchelder, R., Waliyany, S., Neal, J., Witteles, R., Nguyen, P., Cheng, P., Zhu, H.
2023
- **Late-Onset Immunotherapy-Induced Myocarditis 2 Years After Checkpoint Inhibitor Initiation** *JACC: CardioOncology*
Nguyen, A. T., Berry, G. J., Witteles, R. M., Le, D. T., Wu, S. M., Fisher, G. A., Zhu, H.
2022; 4 (5): 727-730
- **Constrictive Pericarditis Revealing Rare Case of ALH Amyloidosis With Underlying Lymphoplasmacytic Lymphoma (Waldenstrom Macroglobulinemia).** *JACC. Case reports*
Ho, V. V., O'Sullivan, J. W., Collins, W. J., Ozdalga, E., Bell, C. F., Shah, N. D., Krishnam, M. S., Ozawa, M. G., Witteles, R. M.
2022; 4 (5): 271-275
- **High-Throughput Precision Phenotyping of Left Ventricular Hypertrophy With Cardiovascular Deep Learning.** *JAMA cardiology*
Duffy, G., Cheng, P. P., Yuan, N., He, B., Kwan, A. C., Shun-Shin, M. J., Alexander, K. M., Ebinger, J., Lungren, M. P., Rader, F., Liang, D. H., Schnittger, I., Ashley, et al
2022
- **Developing Therapy for Transthyretin Amyloidosis.** *The American journal of medicine*
Campbell, C. M., Zhang, K., Lenihan, D. J., Witteles, R.
1800
- **The Role of Single-Cell Profiling and Deep Immunophenotyping in Understanding Immune Therapy Cardiotoxicity** *JACC: CardioOncology*
Huang, Y. V., Waliyany, S., Lee, D., Galdos, F. X., Witteles, R. M., Neal, J. W., Fan, A. C., Maecker, H. T., Nguyen, P. K., Wu, S. M., Zhu, H.
2022; 4 (5): 629-634
- **Ibrutinib-associated atrial fibrillation treatment with catheter ablation.** *HeartRhythm case reports*
Kapoor, R., Fazal, M., Cheng, P., Witteles, R., Rhee, J., Baykaner, T.
2021; 7 (11): 713-716
- **Misconceptions and Facts About Cardiac Amyloidosis.** *The American journal of cardiology*
Nguyen, F. D., Rodriguez Rivera, M., Krittanawong, C., Witteles, R., Lenihan, D. J.
2021
- **Graded cardiac response criteria for AL amyloidosis: the impact of depth of cardiac response on survival**
Muchtar, E. Y., Dispenzieri, A., Wisniewski, B., Palladini, G., Milani, P., Merlini, G., Schonland, S., Veelkan, K., Hegenbart, U., Kumar, S., Kastritis, E., Dimopoulos, M., Liedtke, et al
CIG MEDIA GROUP, LP.2021: S24-S25
- **Graded renal response criteria and revised renal progression criteria for light chain (AL) amyloidosis**
Muchtar, E., Wisniewski, B., Palladini, G., Milani, P., Merlini, G., Schonland, S., Veelkan, K., Hegenbart, U., Dispenzieri, A., Kumar, S., Leung, N., Kastritis, E., Dimopoulos, et al
CIG MEDIA GROUP, LP.2021: S23-S24
- **Pharmacovigilance analysis of cardiac toxicities associated with targeted therapies for metastatic non-small cell lung carcinoma.** *Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer*
Waliyany, S., Zhu, H., Wakelee, H., Padda, S. K., Das, M., Ramchandran, K., Myall, N. J., Chen, T., Witteles, R. M., Neal, J. W.
2021
- **Corrigendum to 'TNF-alpha Inhibition for the Treatment of Cardiac Sarcoidosis' Seminars in Arthritis and Rheumatism. 2020**
Jun;50(3):546-552. Seminars in arthritis and rheumatism

- Baker, M. C., Sheth, K., Witteles, R., Genovese, M. C., Shoor, S., Simard, J. F.
2021
- **Racial and Ethnic Disparities in Cardio-Oncology A Call to Action** *JACC: CARDIOONCOLOGY*
Fazal, M., Malisa, J., Rhee, J., Witteles, R. M., Rodriguez, F.
2021; 3 (2): 201-204
 - **Racial and Ethnic Disparities in Transthyretin Cardiac Amyloidosis.** *Current cardiovascular risk reports*
Spencer-Bonilla, G., Njoroge, J. N., Pearson, K., Witteles, R. M., Aras, M. A., Alexander, K. M.
2021; 15 (6)
 - **Racial and Ethnic Disparities in Cardio-Oncology: A Call to Action.** *JACC. CardioOncology*
Fazal, M., Malisa, J., Rhee, J. W., Witteles, R. M., Rodriguez, F.
2021; 3 (2): 201-204
 - **Myocarditis Surveillance with High-Sensitivity Troponin I During Cancer Treatment with Immune Checkpoint Inhibitors.** *JACC. CardioOncology*
Waliany, S., Neal, J. W., Reddy, S., Wakelee, H., Shah, S. A., Srinivas, S., Padda, S. K., Fan, A. C., Colevas, A. D., Wu, S. M., Witteles, R. M., Zhu, H.
2021; 3 (1): 137-39
 - **Racial and Ethnic Disparities in Transthyretin Cardiac Amyloidosis** *Curr Cardiovasc Risk Rep*
Spencer-Bonilla, G., Njoroge, J. N., Pearson, K., Witteles, R. M., Aras, M. A., Alexander, K. M.
2021
 - **Mitochondria-Rich Extracellular Vesicles Rescue Patient-Specific Cardiomyocytes From Doxorubicin Injury: Insights Into the SENECA Trial.** *JACC. CardioOncology*
O'Brien, C. G., Ozen, M. O., Ikeda, G., Vaskova, E., Jung, J. H., Bayardo, N., Santoso, M. R., Shi, L., Wahlquist, C., Jiang, Z., Jung, Y., Zeng, Y., Egan, et al
2021; 3 (3): 428-440
 - **Cardiac Transplantation and Mechanical Circulatory Support in Amyloidosis.** *JACC. CardioOncology*
Witteles, R. M.
2021; 3 (4): 516-521
 - **Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey.** *JACC. CardioOncology*
Nativi-Nicolau, J., Siu, A., Dispenzieri, A., Maurer, M. S., Rapezzi, C., Kristen, A. V., Garcia-Pavia, P., LoRusso, S., Waddington-Cruz, M., Lairez, O., Witteles, R., Chapman, D., Amass, et al
2021; 3 (4): 537-546
 - **Arrhythmia Patterns in Patients on Ibrutinib.** *Frontiers in cardiovascular medicine*
Fazal, M., Kapoor, R., Cheng, P., Rogers, A. J., Narayan, S. M., Wang, P., Witteles, R. M., Perino, A. C., Baykaner, T., Rhee, J.
1800; 8: 792310
 - **Functional Capacity, Health-related Quality-of-life and Cardiac Biomarker Improvement with Tafamidis in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT)**
Hanna, M., Fine, N., Stewart, M., Gundapaneni, B., Sultan, M. B., Witteles, R.
CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS.2020: S65
 - **Temporal Trends of Wild-type Attr Amyloidosis in the Transthyretin Amyloidosis Outcomes Survey**
Nativi-Nicolau, J., Siu, A., Dispenzieri, A., Maurer, M. S., Rapezzi, C., Kristen, A., Garcia-Pavia, P., LoRusso, S., Waddington-Cruz, M., Lairez, O., Witteles, R., Chapman, D., Rill, et al
CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS.2020: S82
 - **REPLY: Should We Be for ASCT? If Yes, Then When?** *JACC-HEART FAILURE*
Witteles, R. M., Barrett, C. D.
2020; 8 (8): 696-97
 - **Immune Profiling and Causal Antigen Discovery in Mouse and Human Models of Immune Checkpoint Inhibitor-induced Myocarditis**

Zhu, H., Lee, D., Sarah, W., Galdos, F. X., D'Addabbo, J., Fowler, M. B., Reddy, S., Heather, W., Neal, J. W., Witteles, R., Maecker, H. T., Davis, M., Nguyen, et al
LIPPINCOTT WILLIAMS & WILKINS.2020

- **Cardiac Scintigraphy With Technetium-99m-Labeled Bone -Seeking Tracers for Suspected Amyloidosis JACC Review Topic of the Week** *JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY*
Hanna, M., Ruberg, F. L., Maurer, M. S., Dispenzieri, A., Dorbala, S., Falk, R. H., Hoffman, J., Jaber, W., Soman, P., Witteles, R. M., Grogan, M. 2020; 75 (22): 2851–62
- **Cardiac Scintigraphy With Technetium-99m-Labeled Bone-Seeking Tracers for Suspected Amyloidosis: JACC Review Topic of the Week.** *Journal of the American College of Cardiology*
Hanna, M., Ruberg, F. L., Maurer, M. S., Dispenzieri, A., Dorbala, S., Falk, R. H., Hoffman, J., Jaber, W., Soman, P., Witteles, R. M., Grogan, M. 2020; 75 (22): 2851–62
- **Correction to: Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response.** *Current cardiology reports*
Zhu, H., Rhee, J., Cheng, P., Waliany, S., Chang, A., Witteles, R. M., Maecker, H., Davis, M. M., Nguyen, P. K., Wu, S. M. 2020; 22 (5): 36
- **A pilot study of F-18-FSPG SiPM-based PET/CT in patients referred for exclusion of active cardiac sarcoidosis and negative or non-diagnostic F-18-FDG PET/CT**
Duan, H., Hatami, N., Baratto, L., Davidzon, G., Aparici, C., Gambhir, S., Koglin, N., Witteles, R., Iagaru, A.
SOC NUCLEAR MEDICINE INC.2020
- **Portable Ultrasound Device Usage and Learning Outcomes Among Internal Medicine Trainees: A Parallel-Group Randomized Trial.** *Journal of hospital medicine*
Kumar, A., Weng, Y., Wang, L., Bentley, J., Almlı, M., Hom, J., Witteles, R., Ahuja, N., Kugler, J. 2020; 15 (2): e1–e6
- **Bone Scintigraphy Imaging for Transthyretin Cardiac Amyloidosis: Still Much to Learn.** *JACC. Cardiovascular imaging*
Alexander, K. M., Witteles, R. M. 2020
- **Organ responses with daratumumab therapy in previously treated AL amyloidosis.** *Blood advances*
Chung, A. n., Kaufman, G. P., Sidana, S. n., Eckhart, E. n., Schrier, S. L., Lafayette, R. A., Arai, S. n., Witteles, R. M., Liedtke, M. n. 2020; 4 (3): 458–66
- **Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response** *Curr Cardiol Rep*
Zhu, H., Rhee, J., Cheng, P., Waliany, S., Chang, A., Witteles, R. M., Maecker, H., Davis, M. M., Nguyen, P. K., Wu, S. M. 2020; 22 (5)
- **Outcomes in Patients With Cardiac Amyloidosis Undergoing Heart Transplantation.** *JACC. Heart failure*
Barrett, C. D., Alexander, K. M., Zhao, H. n., Haddad, F. n., Cheng, P. n., Liao, R. n., Wheeler, M. T., Liedtke, M. n., Schrier, S. n., Arai, S. n., Weisshaar, D. n., Witteles, R. M. 2020
- **Cardiovascular Risks in Patients with COVID-19: Potential Mechanisms and Areas of Uncertainty.** *Current cardiology reports*
Cheng, P. n., Zhu, H. n., Witteles, R. M., Wu, J. C., Quertermous, T. n., Wu, S. M., Rhee, J. W. 2020; 22 (5): 34
- **Letter regarding the article 'Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study'.** *European journal of heart failure*
Damy, T. n., Sultan, M. B., Witteles, R. n. 2020
- **Immune Checkpoint Inhibitor Cardiotoxicity: Understanding Basic Mechanisms and Clinical Characteristics and Finding a Cure.** *Annual review of pharmacology and toxicology*
Waliany, S. n., Lee, D. n., Witteles, R. M., Neal, J. W., Nguyen, P. n., Davis, M. M., Salem, J. E., Wu, S. M., Moslehi, J. J., Zhu, H. n. 2020
- **Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner.** *BMC family practice*

- Gertz, M. n., Adams, D. n., Ando, Y. n., Beirão, J. M., Bokhari, S. n., Coelho, T. n., Comenzo, R. L., Damy, T. n., Dorbala, S. n., Drachman, B. M., Fontana, M. n., Gillmore, J. D., Grogan, et al
2020; 21 (1): 198
- **Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a Position Statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society.** *European journal of heart failure*
Lyon, A. R., Dent, S. n., Stanway, S. n., Earl, H. n., Brezden-Masley, C. n., Cohen-Solal, A. n., Tocchetti, C. G., Moslehi, J. n., Groarke, J. D., Bergler-Klein, J. n., Khoo, V. n., Tan, L. L., Anker, et al
2020
 - **Long-Term Safety and Efficacy of AG10 in Patients With Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Interim Analysis of the Ongoing Phase 2 Open-Label Extension Study**
Judge, D., Heitner, S. B., Falk, R. H., Grogan, M., Jacoby, D. L., Maurer, M. S., Selby, V. N., Shah, S. J., Witteles, R., Katz, L., Rao, S., Sinha, U., Fox, et al
LIPPINCOTT WILLIAMS & WILKINS.2019: E966–E967
 - **Long-Term Outcomes and Organ Responses with Daratumumab Therapy in Previously Treated Patients with AL Amyloidosis**
Chung, A., Kaufman, G. P., Sidana, S., Eckhert, E., Schrier, S., Arai, S., Lafayette, R., Witteles, R., Liedtke, M.
AMER SOC HEMATOLOGY.2019
 - **Favorable Long-Term Outcomes after Daratumumab Discontinuation in AL Amyloidosis Patients Achieving Deep Responses**
Chung, A., Kaufman, G. P., Sidana, S., Iberri, D., Eckhert, E., Schrier, S., Lafayette, R., Arai, S., Witteles, R., Liedtke, M.
AMER SOC HEMATOLOGY.2019
 - **Diagnosis and Treatment of Cardiac Amyloidosis Related to Plasma Cell Dyscrasias.** *Cardiology clinics*
Alexander, K. M., Evangelisti, A., Witteles, R. M.
2019; 37 (4): 487–95
 - **Increase in Blood Pressure Associated With Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor.** *JACC. CardioOncology*
Waliany, S., Sainani, K. L., Park, L. S., Zhang, C. A., Srinivas, S., Witteles, R. M.
2019; 1 (1): 24-36
 - **AL Amyloidosis for the Cardiologist and Oncologist: Epidemiology, Diagnosis, and Management.** *JACC. CardioOncology*
Witteles, R. M., Liedtke, M.
2019; 1 (1): 117-130
 - **Human-induced Pluripotent Stem Cell-derived Cardiomyocytes as a Model for Trastuzumab-Induced Cardiac Dysfunction**
Kitani, T., Ong, S., Lam, C. K., Rhee, J., Zhang, J. Z., Oikonomopoulos, A., Ma, N., Tian, L., Lee, J., Telli, M. L., Witteles, R. M., Sharma, A., Sayed, et al
LIPPINCOTT WILLIAMS & WILKINS.2019
 - **Efficacy and Safety of Tafamidis Doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT)**
Hanna, M., Damy, T., Garcia-Pavia, P., Judge, D. P., Merlini, G., Maurer, M. S., Gundapaneni, B., Patterson, T. A., Schwartz, J. H., Sultan, M. B., Witteles, R.
CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS.2019: S77–S78
 - **Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy** *JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY*
Judge, D. P., Heitner, S. B., Falk, R. H., Maurer, M. S., Shah, S. J., Witteles, R. M., Grogan, M., Selby, V. N., Jacoby, D., Hanna, M., Nativi-Nicolau, J., Patel, J., Rao, et al
2019; 74 (3): 285–95
 - **Grading cardiac response in AL amyloidosis: implications for relapse and survival** *BRITISH JOURNAL OF HAEMATOLOGY*
Eckhert, E., Witteles, R., Kaufman, G., Lafayette, R., Arai, S., Schrier, S., O'Shaughnessy, M., Liedtke, M.
2019; 186 (1): 144–46
 - **Human-Induced Pluripotent Stem Cell Model of Trastuzumab-Induced Cardiac Dysfunction in Patients With Breast Cancer** *CIRCULATION*
Kitani, T., Ong, S., Lam, C., Rhee, J., Zhang, J. Z., Oikonomopoulos, A., Ma, N., Tian, L., Lee, J., Telli, M. L., Witteles, R. M., Sharma, A., Sayed, et al
2019; 139 (21): 2451–65

- **Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy.** *Journal of the American College of Cardiology*
Judge, D. P., Falk, R. H., Maurer, M. S., Shah, S. J., Witteles, R. M., Grogan, M., Selby, V. N., Jacoby, D., Hanna, M., Nativi-Nicolau, J., Patel, J., Rao, S., Sinha, et al
2019
- **Doxycycline and Ursodiol for ATTR Amyloidosis: Not Ready for Prime Time** *JOURNAL OF CARDIAC FAILURE*
Witteles, R. M.
2019; 25 (3): 154–55
- **REPLY: Increasingly Recognized Role of Right Ventricle Assessment in Cardiac Amyloidosis** *JACC-HEART FAILURE*
Amsallem, M., Witteles, R., Haddad, F.
2019; 7 (3): 279–80
- **Serial Cardiac FDG-PET for the Diagnosis and Therapeutic Guidance of Patients with Cardiac Sarcoidosis.** *Journal of cardiac failure*
Ning, N., Guo, H. H., Iagaru, A., Mittra, E., Fowler, M., Witteles, R.
2019
- **Doxycycline and Ursodiol for ATTR Amyloidosis: Not Ready for Prime Time.** *Journal of cardiac failure*
Witteles, R.
2019
- **Management of Cardiac Amyloidosis: Do's and Don'ts.** *The Canadian journal of cardiology*
Alexander, K. M., Witteles, R. M.
2019
- **TNF-alpha inhibition for the treatment of cardiac sarcoidosis.** *Seminars in arthritis and rheumatism*
Baker, M. C., Sheth, K. n., Witteles, R. n., Genovese, M. C., Shoor, S. n., Simard, J. F.
2019
- **Thrombophilia testing in the inpatient setting: impact of an educational intervention.** *BMC medical informatics and decision making*
Kwang, H. n., Mou, E. n., Richman, I. n., Kumar, A. n., Berube, C. n., Kaimal, R. n., Ahuja, N. n., Harman, S. n., Johnson, T. n., Shah, N. n., Witteles, R. n., Harrington, R. n., Shieh, et al
2019; 19 (1): 167
- **Genomics in medicine: a novel elective rotation for internal medicine residents.** *Postgraduate medical journal*
Geng, L. N., Kohler, J. N., Levonian, P. n., Bernstein, J. A., Ford, J. M., Ahuja, N. n., Witteles, R. n., Hom, J. n., Wheeler, M. n.
2019
- **Human Induced Pluripotent Stem Cell Model of Trastuzumab-Induced Cardiac Dysfunction in Breast Cancer Patients.** *Circulation*
Kitani, T. n., Ong, S. G., Lam, C. K., Rhee, J. W., Zhang, J. Z., Oikonomopoulos, A. n., Ma, N. n., Tian, L. n., Lee, J. n., Telli, M. L., Witteles, R. M., Sharma, A. n., Sayed, et al
2019
- **Emerging Therapies for Transthyretin Cardiac Amyloidosis.** *Current treatment options in cardiovascular medicine*
Alexander, K. M., Evangelisti, A. n., Witteles, R. M.
2019; 21 (8): 40
- **Grading cardiac response in AL amyloidosis: implications for relapse and survival.** *British journal of haematology*
Eckhart, E., Witteles, R., Kaufman, G., Lafayette, R., Arai, S., Schrier, S., O'Shaughnessy, M., Liedtke, M.
2018
- **Safety, Tolerability and Transthyretin Stabilization by AG10: A Phase 2, Randomized, Double-blind, Placebo-controlled Clinical Trial in Patients with Transthyretin Amyloid Cardiomyopathy and NYHA Class II/III Heart Failure**
Judge, D. P., Falk, R., Grogan, M., Heitner, S. B., Jacoby, D., Maurer, M., Selby, V. N., Shah, S. J., Witteles, R. M., Hanna, M., Patel, J., Nativi-Nicolau, J., Rao, et al
LIPPINCOTT WILLIAMS & WILKINS.2018: E770
- **Graded Cardiac Response Correlates with Relapse and Survival in AL Amyloidosis**
Eckhart, E., Witteles, R., Kaufman, G., Lafayette, R., Arai, S., Schrier, S., O'Shaughnessy, M., Liedtke, M.
AMER SOC HEMATOLOGY.2018

- **Efficacy of Tafamidis in Transthyretin Amyloid Cardiomyopathy in the ATTR-ACT Trial: Sensitivity Analyses Further Support the Primary Results**
Maurer, M. S., Schwartz, J. H., Gundapaneni, B., Elliott, P., Merlini, G., Cruz, M., Kristen, A. V., Grogan, M., Witteles, R., Damy, T., Drachman, B. M., Shah, S. J., Hanna, et al
CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS.2018: 813
- **Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.** *The New England journal of medicine*
Maurer, M. S., Schwartz, J. H., Gundapaneni, B., Elliott, P. M., Merlini, G., Waddington-Cruz, M., Kristen, A. V., Grogan, M., Witteles, R., Damy, T., Drachman, B. M., Shah, S. J., Hanna, et al
2018
- **¹⁸F-florbetaben whole-body PET/MRI for evaluation of systemic amyloid deposition.** *EJNMMI research*
Baratto, L., Park, S. Y., Hatami, N., Gulaka, P., Vasanaawala, S., Yohannan, T. K., Herfkens, R., Witteles, R., Iagaru, A.
2018; 8 (1): 66
- **F-18-florbetaben whole-body PET/MRI for evaluation of systemic amyloid deposition** *EJNMMI RESEARCH*
Baratto, L., Park, S., Hatami, N., Gulaka, P., Vasanaawala, S., Yohannan, T., Herfkens, R., Witteles, R., Iagaru, A.
2018; 8
- **SERIAL CARDIAC FDG-PET IN THE DIAGNOSIS AND THERAPEUTIC GUIDANCE OF PATIENTS WITH CARDIAC SARCOIDOSIS: A STANFORD EXPERIENCE**
Ning, N., Guo, H. H., Jagaru, A., Mitra, E., Fowler, M., Witteles, R.
ELSEVIER SCIENCE INC.2018: 1690
- **Atrial Septal Defect as Unexpected Cause of Pulmonary Artery Hypertension** *TEXAS HEART INSTITUTE JOURNAL*
Parikh, R., Boyd, J., Lee, D. P., Witteles, R.
2018; 45 (1): 42–44
- **A high value care curriculum for interns: a description of curricular design, implementation and housestaff feedback** *POSTGRADUATE MEDICAL JOURNAL*
Hom, J., Kumar, A., Evans, K. H., Svec, D., Richman, I., Fang, D., Smeraglio, A., Holubar, M., Johnson, T., Shah, N., Renault, C., Ahuja, N., Witteles, et al
2017; 93 (1106): 725–29
- **Carcinoid Syndrome Complicating a Pancreatic Neuroendocrine Tumor A Case Report** *PANCREAS*
Gerson, J. N., Witteles, R. M., Chang, D. T., Beygui, R. E., Iagaru, A. H., Kunz, P. L.
2017; 46 (10): 1381–85
- **Epidemiology and Clinical Implications of Gastrointestinal Symptoms in Systemic Amyloidosis**
Yen, T., Chen, F., Witteles, R., Liedtke, M., Nguyen, L.
NATURE PUBLISHING GROUP.2017: S240
- **Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis** *BLOOD*
Kaufman, G. P., Schrier, S. L., Lafayette, R. A., Arai, S., Witteles, R. M., Liedtke, M.
2017; 130 (7): 900–902
- **WHOLE HEART OF THE MATTER**
Parikh, R., Boyd, J., Lee, D., Witteles, R.
ELSEVIER SCIENCE INC.2017: 2411
- **A high value care curriculum for interns: a description of curricular design, implementation and housestaff feedback.** *Postgraduate medical journal*
Hom, J. n., Kumar, A. n., Evans, K. H., Svec, D. n., Richman, I. n., Fang, D. n., Smeraglio, A. n., Holubar, M. n., Johnson, T. n., Shah, N. n., Renault, C. n., Ahuja, N. n., Witteles, et al
2017
- **Functional Cardiac Recovery and Hematologic Response to Chemotherapy in Patients With Light-Chain Amyloidosis (from the Stanford University Amyloidosis Registry).** *The American journal of cardiology*
Tuzovic, M. n., Kobayashi, Y. n., Wheeler, M. n., Barrett, C. n., Liedtke, M. n., Lafayette, R. n., Schrier, S. n., Haddad, F. n., Witteles, R. n.
2017; 120 (8): 1381–86

- **A 15-year review of the Stanford Internal Medicine Residency Program: predictors of resident satisfaction and dissatisfaction** *ADVANCES IN MEDICAL EDUCATION AND PRACTICE*
Kahn, J. S., Witteles, R. M., Mahaffey, K. W., Desai, S. A., Ozdalga, E., Heidenreich, P. A.
2017; 8: 559–66
- **Hematologic Responses and Cardiac Organ Improvement in Patients with Heavily Pretreated Cardiac Immunoglobulin Light Chain (AL) Amyloidosis Receiving Daratumumab**
Kaufman, G., Witteles, R., Wheeler, M., Ulloa, P., Lugtu, M., Arai, S., Schrier, S., Lafayette, R., Liedtke, M.
AMER SOC HEMATOLOGY.2016
- **Prevalence and Financial Impact of Inappropriate Thrombophilia Testing in the Inpatient Hospital Setting: A Retrospective Analysis**
Mou, E., Kwang, H., Hom, J., Shieh, L., Ahuja, N., Harman, S., Johnson, T., Kumar, A., Shah, N., Witteles, R., Berube, C.
AMER SOC HEMATOLOGY.2016
- **Accreditation Council for Graduate Medical Education (ACGME) Milestones-Time for a Revolt?** *JAMA internal medicine*
Witteles, R. M., Verghese, A.
2016; 176 (11): 1599-1600
- **The State of Medical Student Performance Evaluations: Improved Transparency or Continued Obfuscation?** *ACADEMIC MEDICINE*
Hom, J., Richman, I., Hall, P., Ahuja, N., Harman, S., Harrington, R., Witteles, R.
2016; 91 (11): 1534–39
- **A resident-created hospitalist curriculum for internal medicine housestaff.** *Journal of hospital medicine*
Kumar, A., Smeraglio, A., Witteles, R., Harman, S., Nallamshetty, S., Rogers, A., Harrington, R., Ahuja, N.
2016; 11 (9): 646-649
- **Patient Outcomes when Housestaff Exceed 80 Hours per Week.** *American journal of medicine*
Ouyang, D., Chen, J. H., Krishnan, G., Hom, J., Witteles, R., Chi, J.
2016; 129 (9): 993-999 e1
- **Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey).** *Journal of the American College of Cardiology*
Maurer, M. S., Hanna, M., Grogan, M., Dispenzieri, A., Witteles, R., Drachman, B., Judge, D. P., Lenihan, D. J., Gottlieb, S. S., Shah, S. J., Steidley, D. E., Ventura, H., Murali, et al
2016; 68 (2): 161-172
- **Genotype and Phenotype of Transthyretin Cardiac Amyloidosis THAOS (Transthyretin Amyloid Outcome Survey)** *JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY*
Maurer, M. S., Hanna, M., Grogan, M., Dispenzieri, A., Witteles, R., Drachman, B., Judge, D. P., Lenihan, D. J., Gottlieb, S. S., Shah, S. J., Steidley, D. E., Ventura, H., Murali, et al
2016; 68 (2): 161-172
- **Biomarkers as Predictors of Cardiac Toxicity From Targeted Cancer Therapies** *JOURNAL OF CARDIAC FAILURE*
Witteles, R. M.
2016; 22 (6): 459-464
- **Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity** *NATURE MEDICINE*
Burrige, P. W., Li, Y. F., Matsa, E., Wu, H., Ong, S., Sharma, A., Holmstrom, A., Chang, A. C., Coronado, M. J., Ebert, A. D., Knowles, J. W., Telli, M. L., Witteles, et al
2016; 22 (5): 547-556
- **Response to Letter Regarding Article, "Myocardial Protection During Cardiotoxic Chemotherapy"** *CIRCULATION*
Witteles, R. M., Bosch, X.
2016; 133 (15): E598
- **Myocardial Protection During Cardiotoxic Chemotherapy** *CIRCULATION*
Witteles, R. M., Bosch, X.
2015; 132 (19): 1835–45
- **FROM PALPITATIONS TO CARDIOVASCULAR COLLAPSE: THE STORY OF A PHEOCHROMOCYTOMA**

- Flint, K. M., Witteles, R.
ELSEVIER SCIENCE INC.2015: A618
- **Radiation-induced heart disease: an under-recognized entity?** *Current treatment options in cardiovascular medicine*
Davis, M., Witteles, R. M.
2014; 16 (6): 317-?
 - **Reply to "heart failure and breast cancer: emerging controversies regarding some cardioprotective strategies".** *Journal of cardiac failure*
Witteles, R. M., Thakur, A.
2014; 20 (6): 457-?
 - **Cancer therapy-induced left ventricular dysfunction: interventions and prognosis.** *Journal of cardiac failure*
Thakur, A., Witteles, R. M.
2014; 20 (3): 155-158
 - **Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement.** *Haematologica*
Dinner, S., Witteles, W., Afghahi, A., Witteles, R., Arai, S., Lafayette, R., Schrier, S. L., Liedtke, M.
2013; 98 (10): 1593-1599
 - **Chemotherapy-Induced Left Ventricular Dysfunction: Interventions and Prognosis**
Thakur, A., Witteles, R. M.
CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS.2013: S86–S87
 - **AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin** *PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA*
Penchala, S. C., Connelly, S., Wang, Y., Park, M. S., Zhao, L., Baranczak, A., Rappley, I., Vogel, H., Liedtke, M., Witteles, R. M., Powers, E. T., Reixach, N., Chan, et al
2013; 110 (24): 9992-9997
 - **The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis** *BRITISH JOURNAL OF HAEMATOLOGY*
Dinner, S., Witteles, W., Witteles, R., Lam, A., Arai, S., Lafayette, R., George, T. I., Schrier, S. L., Liedtke, M.
2013; 161 (3): 367-372
 - **Development of a reproducible FDG PET/CT cardiac imaging protocol for the evaluation of cardiac sarcoidosis**
Kulm, J., Mitra, E., Guo, H., Witteles, R., Quon, A.
SOC NUCLEAR MEDICINE INC.2013
 - **Cardiac Testing to Manage Cardiovascular Risk in Cancer Patients** *SEMINARS IN ONCOLOGY*
Davis, M., Witteles, R. M.
2013; 40 (2): 147-155
 - **The Frequency and Severity of Cardiovascular Toxicity From Targeted Therapy in Advanced Renal Cell Carcinoma Patients.** *JACC. Heart failure*
Hall, P. S., Harshman, L. C., Srinivas, S., Witteles, R. M.
2013; 1 (1): 72-78
 - **The Frequency and Severity of Cardiovascular Toxicity From Targeted Therapy in Advanced Renal Cell Carcinoma Patients** *JACC-HEART FAILURE*
Hall, P. S., Harshman, L. C., Srinivas, S., Witteles, R. M.
2013; 1 (1): 72-78
 - **Broken Heart Syndrome (Takotsubo Cardiomyopathy) Triggered by Acute Mania: A Review and Case Report** *PSYCHOSOMATICS*
Maldonado, J. R., Pajouhi, P., Witteles, R.
2013; 54 (1): 74-79
 - **Capecitabine-Induced Chest Pain Relieved by Diltiazem** *AMERICAN JOURNAL OF CARDIOLOGY*
Ambrosy, A. P., Kunz, P. L., Fisher, G. A., Witteles, R. M.
2012; 110 (11): 1623-1626

- **Dipeptidyl Peptidase 4 Inhibition Increases Myocardial Glucose Uptake in Nonischemic Cardiomyopathy** *JOURNAL OF CARDIAC FAILURE*
Witteles, R. M., Keu, K. V., Quon, A., Tavana, H., Fowler, M. B.
2012; 18 (10): 804-809
- **Therapy With a DPP-4 Inhibitor Increases Myocardial Glucose Uptake in Nonischemic Cardiomyopathy**
Witteles, R. M., Keu, K. V., Quon, A., Tavana, H., Fowler, M. B.
CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS.2012: S10
- **Incidence and severity of cardiotoxicity in metastatic renal cell carcinoma (RCC) patients treated with targeted therapies.** *48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)*
Hall, P. S., Witteles, R., Srinivas, S., Harshman, L. C.
AMER SOC CLINICAL ONCOLOGY.2012
- **More Than a Frog in the Throat A Case Series and Review of Localized Laryngeal Amyloidosis** *ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY*
Stevenson, R., Witteles, R., Damrose, E., Arai, S., Lafayette, R. A., Schrier, S., Afghahi, A., Liedtke, M.
2012; 138 (5): 509-511
- **Cardiac Amyloidosis: Screening Criteria for Heart Transplantation and New Strategies for Post-Transplant Therapy** *15th Annual Scientific Meeting of the Heart-Failure-Society-of-America*
Varr, B. C., Liedtke, M., Arai, S., Lafayette, R. A., Schrier, S. L., Witteles, R. M.
CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS.2011: S45-S46
- **Treating Asymptomatic Chemotherapy-Induced Cardiac Dysfunction A Chance That Cardiologists and Oncologists Should Not Miss Reply** *JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY*
Witteles, R. M., Yoon, G., Telli, M., Kao, D. P., Matsuda, K. Y., Carlson, R. W.
2011; 57 (17): 1790-1791
- **OVERUSE OF LEFT VENTRICULOGRAPHY** *60th Annual Scientific Session and Expo of the American-College-of-Cardiology (ACC) / I2 Summit / ACCF/Herman K. Gold Young Investigator's Award in Molecular and Cellular Cardiology*
Witteles, R., Knowles, J. W., Perez, M., Morris, W. H., Spettell, C. M., Brennan, T. A., Heidenreich, P. A.
ELSEVIER SCIENCE INC.2011: E1289-E1289
- **Trastuzumab-Related Cardiac Dysfunction** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Telli, M. L., Witteles, R. M.
2011; 9 (2): 243-249
- **Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial** *LANCET*
Esler, M. D., Krum, H., Sobotka, P. A., Schlaich, M. P., Schmieder, R. E., Boehm, M., Mahfoud, F., Sievert, H., Wunderlich, N., Rump, L. C., Vonend, O., Uder, M., Lobo, et al
2010; 376 (9756): 1903-1909
- **A Pilot Study of Melphalan, Lenalidomide and Dexamethasone In AL Amyloidosis: Interim Results** *52nd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Afghahi, A., Witteles, W., Witteles, R., Liedtke, M., Lafayette, R., Arai, S., Schrier, S. L.
AMER SOC HEMATOLOGY.2010: 810-11
- **AL Amyloidosis and Concomitant Myeloma: Time to Reconsider Assumptions.**
Witteles, W., Witteles, R., Liedtke, M., Arai, S., Lafayette, R., George, T. I., Schrier, S. L.
AMER SOC HEMATOLOGY.2010: 1649
- **Overdiagnosis of Left Ventricular Noncompaction** *14th Annual Scientific Meeting of the Heart-Failure-Society-of-America*
Singh, G. D., Witteles, R. M.
CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS.2010: S107-S107
- **Measurement Precision in the Optimization of Cardiac Resynchronization Therapy** *CIRCULATION-HEART FAILURE*
Turcott, R. G., Witteles, R. M., Wang, P. J., Vagelos, R. H., Fowler, M. B., Ashley, E. A.
2010; 3 (3): 395-404

- **Rosiglitazone Increases Myocardial Glucose Metabolism in Insulin-Resistant Cardiomyopathy** *JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY*
Kao, D. P., Witteles, R. M., Quon, A., Wu, J. C., Gambhir, S. S., Fowler, M. B.
2010; 55 (9): 926-927
- **Nesiritide, Heart Failure, and Renal Dysfunction: Irrational Exuberance or Throwing the Baby out with the Bathwater Editorial to: "Impact of Nesiritide on Renal Function and Mortality in Patients Suffering from Heart Failure" by Dontas et al.** *CARDIOVASCULAR DRUGS AND THERAPY*
Witteles, R. M.
2009; 23 (3): 183-186
- **Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies: Are clinicians responding appropriately?** *45th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)*
Telli, M. L., Yoon, G., Kao, D., Matsuda, K., Witteles, R. M.
AMER SOC CLINICAL ONCOLOGY.2009
- **Left Ventricular Dysfunction in Patients Receiving Cardiotoxic Cancer Therapies: Are Clinicians Responding Appropriately?** *58th Annual Scientific Session of the American-College-of-Cardiology*
Yoon, G., Telli, M., Kao, D., Matsuda, K., Witteles, R.
ELSEVIER SCIENCE INC.2009: A173-A173
- **Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate** *ANNALS OF ONCOLOGY*
Telli, M. L., Witteles, R. M., Fisher, G. A., Srinivas, S.
2008; 19 (9): 1613-1618
- **Impedance cardiography is superior to echocardiographic methods for pacing interval optimization**
Turcott, R. G., Witteles, R. M., Wang, P. J., Vagelos, R. H., Fowler, M. B., Ashley, E. A.
CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS.2008: S65
- **Insulin resistance in chronic heart failure - Reply** *JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY*
Witteles, R. M., Fowler, M. B.
2008; 52 (3): 239-240
- **Independent AV/AVV pacing optimization requires operation along mechanical AV delay isochrones**
Turcott, R. G., Witteles, R., Wang, P. J., Ashley, E. A.
ELSEVIER SCIENCE INC.2008: A21
- **Trastuzumab cardiotoxicity: Clinical management of asymptomatic declines in left ventricular function** *The American Journal of Hematology/Oncology*
Telli ML, Witteles RM, Hunt SA, Carlson RW, Guardino AE
2008; 7 (1): 38-41
- **Reversible high-output cardiac failure, an unusual marker of disease status in multiple myeloma** *LEUKEMIA & LYMPHOMA*
Kohrt, H., Logan, A., Temmins, C., Witteles, R., Liedtke, M., Medeiros, B.
2008; 49 (3): 581-585
- **Reversible high-output cardiac failure, an unusual marker of disease status in multiple myeloma** *Leukemia and Lymphoma*
Kohrt H, Logan A, Temmins C, Witteles R, Liedtke M, Medeiros B
2008; 49: 581-585
- **Reversibility of trastuzumab cardiotoxicity: Is the concept alive and well? Reply** *JOURNAL OF CLINICAL ONCOLOGY*
Telli, M. L., Carlson, R. W., Guardino, A. E., Hunt, S. A., Witteles, R. M.
2007; 25 (34): 5533-5534
- **Nesiritide does not cause renal dysfunction in acute decompensated heart failure: A randomized, double-blind, placebo-controlled clinical trial**
Witteles, R. M., Kao, D., Vagelos, R., Christopherson, D., Matsuda, K., Schreiber, D., Fowler, M. B.
ELSEVIER SCIENCE INC.2007: 63A
- **Reversibility of trastuzumab cardiotoxicity: Is the concept alive and well?** *Journal of Clinical Oncology*
Telli ML, Carlson RW, Guardino AE, Hunt SA, Witteles RM.

2007; 25 (34): 5533-5534

- **Premature ventricular contractions causing pacemaker-mediated tachycardia: A failure of postventricular atrial refractory period after premature ventricular contraction extension?** *HEART RHYTHM*
Witteles, R., Engel, G., Wang, P. J., Al-Ahmad, A.
2005; 2 (12): 1389-1390
- **B-type natriuretic peptide is effective therapy before care** *ANNALS OF INTERNAL MEDICINE*
Witteles, R., Matsuda, K., Fowler, M. B.
2004; 141 (11): 895
- **B-type natriuretic peptide is effective therapy before cardiac transplantation** *Annals of Internal Medicine*
Witteles R, Matsuda K, Fowler MB
2004; 141 (11): 895
- **High prevalence of impaired glucose metabolism in patients with idiopathic dilated cardiomyopathy**
Jamali, A. H., Witteles, R. M., Tang, W. H., Chu, J. W., Reaven, G. M., Fowler, M. B.
ELSEVIER SCIENCE INC.2002: 181A-181A
- **Parathyroid carcinoma** *Surgery of the thyroid and parathyroid glands*
Witteles RM, Straus FH, Koka MLR, Kaplan EL
2002: 46.1-46.13
- **Neuroendocrine tumors of the pancreas** *The Practice of General Surgery*
Buell J, Witteles RM, Koka MLR, Sugg SL, Kaplan EL
2002: 1083-1093
- **Adult-onset nesidioblastosis causing hypoglycemia: An important clinical entity and continuing treatment dilemma** *Archives of Surgery*
Witteles RM, Straus II FH, Sugg SL, Koka MR, Costa EA, Kaplan EL
2001; 136 (6): 656-663
- **Episodic hypertension associated with sitting on hard surfaces** *Journal of General Internal Medicine*
Witteles RM
2001; 16: 70
- **A new provocative test for the diagnosis of pheochromocytoma?** *American Journal of Anesthesiology*
Witteles R, Roizen MF
2001; 28: 446-447
- **Sensitivity of diagnostic and localization tests for pheochromocytoma in clinical practice** *Archives of Internal Medicine*
Witteles RM, Kaplan EL, Roizen MF
2000; 160 (16): 2521-2524
- **Safe and cost-effective preoperative preparation of patients with pheochromocytoma** *Anesthesia and Analgesia*
Witteles RM, Kaplan EL, Roizen MF
2000; 91 (2): 302-304